Abstract. Since the sodium/iodide symporter (NIS) stimulates the iodine uptake in normal lactating breast, our study aimed to study the effect of NIS-mediated radioiodide therapy on ER-negative breast cancers. A recombinant lentivirus plasmid encoding the human NIS (hNIS) gene and firefly luciferase (Fluc) was constructed. MDA-MB-231 cells were transfected with the recombinant lentivirus, and the hNIS gene expression was identified by western blot analysis and real-time PCR. Tissue-specific expression of the NIS gene was confirmed by immunohistochemical (IHC) staining. Functional NIS activity in the MDA-hNIS cells was confirmed by the uptake of $^{131}$I and cytotoxicity assays. The relative expression level of hNIS mRNA exhibited a 10-fold higher expression in the MDA-hNIS cells compared with the level in the control cells without the endogenous NIS gene. Abundant expression of hNIS protein was noted in the cell membrane compared to the cytoplasm which confirmed the efficient expression of the functional hNIS gene. Iodine uptake into the MDA-hNIS cells was rapid, reaching a maximum after 15 min, followed by a decline. Exposure of the MDA-hNIS cells with $^{131}$I resulted in a time-dependent reduction in colony formation compared with the survival of the control (MDA) cells. Our results confirmed that NIS overexpression enhances the sensitivity of ER-negative breast cancer cells to radioiodide therapy.

Introduction

Breast cancer is the most common cancer in women, accounting for 23% of all female cancers around the globe, and its incidence is rising particularly in developing countries (1). Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, and more than 400,000 will succumb to the disease (2).

Breast cancer is a heterogeneous disease, and risk factors may be differentially associated with the development of distinct tumor subtypes that manifest different biological behaviors and progression (3). In support of this research, there is growing evidence that known breast cancer risk factors vary according to hormone receptor status and perhaps other pathological characteristics of the disease (4-6).

One major way of defining the type of breast cancer is whether or not it is endocrine receptor (estrogen or progesterone receptor)-positive, HER2-positive, triple-negative (not positive to receptors for estrogen, progesterone or HER2) or triple-positive (positive for estrogen receptors, progesterone receptors and HER2) (7,8). These classifications provide oncologists with valuable information about how the tumor acts and what type of treatments may work best. Generally, surgical and radiation treatments are similar for these different types of breast cancer. Drug treatments, such as chemotherapy, endocrine therapies and other medications, usually vary. Drug treatments are targeted to the specific type of cancer (9,10).

Some breast cancers (estimates range between 10 and 17%) are known as ‘triple-negative’ since they lack estrogen and progesterone receptors and do not overexpress the HER2 protein (11). The majority of breast cancers associated with the gene known as BRCA1 are triple-negative (12). Overall, however, they have a poorer prognosis than other types of breast cancers. To date, no targeted therapies such as tamoxifen or Herceptin have been developed to help prevent recurrence in women with triple-negative breast cancer (13). Cancer experts are studying several promising targeted strategies aimed at triple-negative breast cancer.

Even though surgical intervention combined with radiotherapy, chemotherapy and endocrine therapy has achieved beneficial results in many breast cancer treatments; for some
patients, particularly estrogen receptor-negative breast cancer patients, the combined treatment is not as promising as treatment for other types of breast cancers. ER-negative breast cancer accounts for approximately one-third of breast cancers, and has a high invasiveness among tumor subtypes and a high relapse rate (14-16). Unfortunately, ER-negative breast cancer is not very sensitive and often responds poorly to endocrine therapy and chemotherapy; thus, the prognosis is significantly worse compared to ER-positive patients (17-19). Sodium/iodide symporter (Na+/I- symporter, NIS), an intrinsic plasma membrane protein, mediates active iodide transport into the thyroid gland and several extra-thyroidal tissues (19). The uptake of iodine by NIS serves as the basis for thyroid hormone biosynthesis, diagnostic thyroid radionuclide imaging as well as treatment of hyperthyroidism and thyroid cancer by radioactive iodine (19,20). NIS is also detected in the mammary gland, placenta, salivary and digestive gland as well as other types of tissues (19,21-23). Among them, the high expression of NIS in breast cancer is attracting more attention (24,25). However, the relationship between the expression of NIS in ER-negative breast cancer and its clinical significance remains elusive.

The ability of cancerous thyroid cells to actively transport iodine via NIS provides a unique and effective delivery system to detect and target these cells for destruction with therapeutic doses of radioiodide, largely without harming other tissues. Therefore, it seems feasible that radioiodide could be a diagnostic and therapeutic tool for the detection and destruction of other cancers in which NIS is functionally expressed (19).

Radioisotopes (131I) have been successfully used for several decades to treat thyroid cancer after residues and metastasis (26). The prerequisite for this radioiodide therapy is the existence of NIS, which facilitates the uptake of radiiodide in thyroid cancer cells resulting in β-ray emissions which cause irreversible DNA damage, leading to cell death (19). With the success of NIS gene cloning and the use of gene transfer technology it has become possible to introduce the NIS gene into non-thyroidal tumor cells, so that it has a polyiodides function similar to thyroid tissues (23). An important recent discovery was that NIS is functionally expressed in vivo in transgenic mouse mammary tumors and is immunohistochemically detected in over 80% of human breast cancers (21), raising the possibility of using radioiodide as a novel therapy for breast cancer. Other iodide-transporting tissues also may upregulate NIS-mediated 131I sensitivity in these cancer cells.

Materials and methods

Breast cancer tissue sample collection and preparation. Tissue and archived paraffin-embedded samples were obtained from patients diagnosed with breast cancer who underwent surgical resection at the Department of Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. All studies were approved by the Institute Research Medical Ethics Committee of Sun Yat-sen University. All individuals provided informed consent prior to their inclusion in the study.

Immunohistochemical (IHC) analysis of NIS expression in the breast cancer tissues. IHC staining was carried out on formalin-fixed, paraffin-embedded micro-tissue sections (4-µm thick) which were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol and rinsed in phosphate-buffered saline. The antigen was retrieved with microwave treatment in 10 mM citrate buffer (pH 6.0). IHC staining was carried out using the EnVision™ kit (Dako) following the manufacturer's instructions. The endogenous peroxidase activity was quenched by 3% hydrogen peroxide for 10 min. The sections were incubated in the primary polyclonal rabbit anti-NIS antibody (Santa Cruz Biotechnology) at a dilution of 1:200 for 30 min at room temperature. In the negative controls, the primary antibody was substituted by normal goat serum. Then the tissue sections were sequentially incubated with ready-to-use horseradish peroxidase (HRP)-immunoglobulin (Envision™) for 30 min and then were developed with 3'3'-diaminobenzidine (DAB) as a chromogen substrate. The nuclei were counterstained with Meyer's hematoxylin (23).

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA from the breast samples were extracted by TRIzol (Invitrogen). RNA samples from breast cancer and normal breast tissues were pooled in equal amounts in single tubes. The mRNA levels of NIS were examined by real-time PCR. Briefly, complementary DNAs were prepared from the total RNA (10 ng) using the QuantiTect Reverse Transcription kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. Then the RT reaction mixture (1 ml) was subjected to real-time PCR analyses using CFX-96 (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. The thermal cycle profile used was incubation at 50°C for 2 min and denaturing at 95°C for 10 min, followed by 40 cycles of the amplification step. The

In order to study the effect of NIS-mediated radioiodide therapy in ER-negative breast cancers, we constructed a recombinant lentivirus plasmid encoding the hNIS gene. Since
primer sets used were: forward, 5'-CCATCTGGGATGCCTTTGG-3' and reverse, 5'-AAAAGCACACGATCCCTTATTGGT-3'; QuantiTect Primer assay, QT00044723 for hNIS and QT00079247 for human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (both from Qiagen Inc.).

Western blot analysis. Proteins were extracted from the breast cancer and normal breast samples. Relative expression levels of NIS and tubulin were detected by SDS-PAGE with the following antibodies according to the manufacturer's instructions: NIS (catalog bs0448R; Bioss, Beijing, China) and tubulin (catalog 1879-1; Cell Signaling Technology, Inc., Danvers, MA, USA) which was used as a loading control. HRP-conjugated anti-rabbit immunoglobulin (catalog A000981; GenScript USA Inc., Piscataway, NJ, USA) was used as the secondary antibody. Finally, protein bands were imaged on X-ray film (Eastman Kodak Co., Rochester, NY, USA) after incubating PVDF membranes (Millipore Corp., Bedford, MA, USA) with enhanced chemiluminescence (ECL) detection reagent (Forevergen Inc, Guangzhou, China).

Construction of the lentiviral vectors overexpressing hNIS. To generate the recombinant lentivirus plasmid encoding the hNIS gene, the hNIS gene (Genbank, NM_000453) was cloned into the lentivirus vector [CS-CMVsr39tk-I-firefly luciferase (Fluc)] (kindly provided by Professor Irene L. Wapnir of Stanford University) at the 5' NheI and 3' BamHI restriction sites. The NIS gene fragment was ligated to the vector CS-CMVsr39tk-I-Fluc using T4 DNA ligase, generating the CS-CMV-hNIS-I-Fluc plasmid.

Lentivirus infection of ER-negative breast cancer cell lines. The CS-CMV-hNIS-I-Fluc plasmid and packaging helper plasmids, pCMV.R 8.2 and pMD.G, were mixed in a ratio of 9:8:1 and then transfected into 293T cells. The supernatants were collected after 72 h and assayed for its viral titer. Breast cancer MDA-MB-231 cells (HER2/neu-negative) were seeded in 6-well plates at least 24 h before infection. Purified virus was exposed to 30 µCi/ml Na131I and incubated in 5% CO2 at 37°C for 2 and 6 h, respectively. The reaction was terminated by removing the medium containing Na131I and washing the cells twice with HBSS. The cells then were trypsinized, counted and subsequently cultured with growth medium in 6-well plates, and the colony formation was assessed after 10 days. Uptake of 131I was confirmed by Geiger Mueller counter before plating. Cells were then fixed in 70% ethanol and stained with Giemsa staining, and the number of macroscopic colonies was counted. The survival rate was calculated as the percentage of cell colonies in plates treated with 131I compared with those with only HBSS, and the cell survival curves were plotted.

Statistical analysis. All statistical analyses were carried out using the SPSS 13.0 statistical software package. Data are represented as means ± standard deviation (SD). P<0.05 was considered to indicate a statistically significant result.

Results

The level of NIS expression in the breast cancer tissues compared to the normal breast tissues. The NIS protein and mRNA expression levels were confirmed by performing western blot analysis and qRT-PCR. NIS protein (~75 kDa) was expressed in the normal breast tissues, ER-positive and ER-negative breast cancer tissues as well as the thyroid tissues. Tubulin (~55 kDa) was used as an internal control. The NIS protein expression was quantified (Fig. 1A) and the expression of NIS protein in the breast cancer tissues (both in ER-negative or ER-positive) was significantly higher compared to that in the adjacent tissues while significantly lower compare to that in the thyroid tissues (Fig. 1B).

Relative expression of NIS mRNA showed significantly increased expression in the ER-negative cells compared to that in the normal cells. The level of expression of NIS mRNA between normal cells and ER-negative cells was significant (Fig. 1C).

NIS protein expression in the breast cancer tissues is localized in the cytoplasm. IHC detection of cells was carried out for NIS expression in various tissues including ER-positive, ER-negative, thyroid and normal control cells (adjacent tissue) as described previously (43). Compared to the control cells, ER-positive and ER-negative breast cancer tissues showed expression of NIS proteins (brown-colored particles after staining) which was mainly concentrated in the cytoplasm (Fig. 2A). In the thyroid tissues, the NIS proteins were expressed mainly in the cell membrane. The Na/I symporter (NIS) is an integral plasma membrane glycoprotein that mediates active iodine transport into thyroid follicular cells, the first step in thyroid hormone biosynthesis (31). NIS-mediated thyroidal iodine transport from the bloodstream to the colloid...
is a vectorial process made possible by the selective targeting of NIS to the basolateral membrane (19).

In addition, we subjected the breast cancer cell lines (ER-positive and ER-negative) to cell fractionation and analyzed the NIS expression using western blot analysis (Fig. 2B). NIS protein expression in the breast cancer cells was localized poorly in the membrane (≤25%), while in the thyroid tissue membranes it was highly concentrated (≥70%). These results suggest that NIS is mainly expressed in the cytoplasm, so that breast cancer may not be as effective as the thyroid in regards to the uptake of radioactive iodine.

**Breast cancer cell lines overexpressing NIS protein.** Patients with breast cancer may benefit from radioiodine therapy if NIS expression/activity can be increased in the malignant tissues to levels sufficient for therapy (32). Findings (33) have shown that retinoic acid (RA) induces the endogenous NIS expression in many malignant cells, particularly in ER-positive breast cancer.
In our study, we found the results of NIS protein expression in ER-positive and ER-negative cell lines in accordance with the previous studies. The levels of expression of NIS in the ER-negative cell lines MDA-MB-231 and SPBR-3 were very low compared with the high expression levels of RA-induced NIS protein in the MCF-7 cells at different time-points from 0 to 48 h (Fig. 3). Therefore, we constructed a lentivirus vector to introduce the exogenous hNIS gene into the MDA-MB-231 cell line which can upregulate the NIS expression more efficiently.

**Figure 3.** Expression of NIS proteins in ER-positive and ER-negative cell lines. (A) Western blot analysis shows the endogenous NIS protein expression in ER-positive cell line, MCF-7 and ER-negative cell lines, MDA-MB-231 and SPBR-3 at different time-points after RA induction from 0 to 48 h. At 12 and 24 h of growth, the ER-positive cell line, MCF-7, showed high levels of NIS expression. The NIS protein expression in both the ER-negative cell lines was the same at every time-point after RA induction. (B) Relative expression of NIS protein in western blotting from 3 independent experiments was quantified using Image J software. Results are expressed as means ± SD analyzed with ANOVA. *P<0.05. NIS, sodium/iodide symporter; RA, retinoic acid.

**Figure 4.** NIS overexpression in the ER-negative cell line MDA-MB-231. (A) qRT-PCR analysis. Relative expression of hNIS mRNA in normal cell lines (MDA) and a transduced ER-negative cell line of breast cancer overexpressing NIS (MDA-hNIS). MDA-hNIS cells showed a 10-fold higher expression of NIS mRNA compared with the control cells. (B) Western blot analysis to quantify the NIS protein. The NIS protein expression in the MDA-hNIS cells was consistent with the NIS mRNA expression in the normal cells. Tubulin was used as an internal control for western blotting. Experiments were performed in triplicate. (C) Western blot analysis of NIS expression in the cell membrane and cytoplasm. Total, is the total protein expressed in the cytoplasm and cell membrane. Data were normalized to total protein. (D) Relative expression of hNIS in the cell membrane and cytoplasm of the transduced cell lines. Data were normalized to total protein. Results are expressed as means ± SD of 3 independent experiments analyzed with ANOVA. *P<0.05 vs. MDA, †P<0.05 vs. total. NIS, sodium/iodide symporter; hNIS, human NIS.
A concentration of 2x10^5 cells were incubated for 2 and 6 h with toxic clonogenic assay. MDA-hNIS and control cells (MDA) at was estimated by determining the survival of cells in a cytotoxic clonogenic assay. MDA-hNIS and control cells (MDA) were used as a negative control. Results are expressed as means ± SD of 3 independent experiments analyzed with ANOVA. *P<0.05 vs. MDA. hNIS, human NIS; NIS, sodium/iodide symporter.

As shown in Fig. 6, the survival rate, based on the clonogenic assay, was markedly reduced in response to ^131I (P<0.05). Exposure of the MDA-hNIS cells to ^131I resulted in a time-dependent reduction in colony formation of 58% at 2 h and 64% at 6 h, compared with the survival of the control cells (MDA). These results showed that NIS overexpression enhanced the sensitivity of ER-negative breast cancer cells to ^131I.

Discussion

ER-negative breast cancer comprises 15-30% of all breast tumors (depending on the population), and has an earlier age at onset and a worse prognosis compared with ER-positive disease (35). NIS has been widely explored as a potential therapeutic gene for many invasive and malignant cancers. The transfer of the NIS gene using many human and non-human vectors into a variety of tumors, including breast (36) and cervical cancer (37) and prostate carcinoma has shown the capacity to confer radioiodide uptake which has emerged as an important radiation therapy for many cancers.

In a preliminary study, we investigated the endogenous NIS gene expression and evaluated its tissue- and site-specific expression by the IHC analysis of tumor tissue samples obtained from patients diagnosed with breast cancer in our hospital. Type-specific breast cancer samples were analyzed for differential expression of the NIS protein. We found significantly higher levels of NIS expression in ER-negative tissues compared to that in the normal tissues and significantly lower levels than thyroid tissues. ER-negative breast cancer tissues showed expression of NIS proteins which was mainly concentrated in the cytoplasm, whereas thyroid cells showed robust expression in the cell membrane, as uptake of iodine by NIS serves as the basis for thyroid hormone biosynthesis.

We observed a markedly low expression of NIS protein in the membrane of breast cancer cells (<25%), while in the thyroid tissue membranes it was highly concentrated (>70%). These results suggest that NIS is mainly expressed in the cytoplasm, so that breast cancer may not be as effective as the thyroid in uptake of radioactive iodine. The likelihood of iodine transport activity is enhanced whenever NIS is immunohistochemically demonstrated in the plasma membrane. Cell membrane immunoreactivity was not observed in other
normal or benign breast tissues, with the exception of gestational or lactating samples (23).

Other reasons may also be anticipated for the reduced uptake of iodine in breast cancer cells, due to reduced expression of NIS in breast cancer cells. In a previous study, NIS expression was demonstrated by RT-PCR in 2 of 2 fibroadenomata and 6 of 7 breast carcinoma messenger ribonucleic acid isolates. The authors also demonstrated a significantly higher mean total tissue iodine level (80.9±9.5 ng I/mg protein) in 23 benign tumors (fibroadenomata) than those in 19 breast cancers taken from either the tumor (18.2±4.6 ng I/mg) or morphologically normal tissue taken from within the tumor-bearing breast (38). These authors suggested that antibody-mediated inhibition played a major role in the inhibition of $^{125}$I uptake into NIS-transfected CHO cells, as these responses were mediated by serum from breast cancer patients compared to normal female controls.

We hypothesized that the low expression of NIS protein in the cell membrane of ER-negative cancer cells may be a possible reason for the reduced susceptibility to radioiodide therapy in this subgroup of cancer patients. Hence, we constructed a lentivirus vector to introduce the exogenous hNIS gene into the ER-negative cell line MDA-MB-231 which can upregulate NIS expression. The relative expression levels of hNIS mRNA showed a 3-fold higher expression in the MDA-hNIS cells compared with the control cells without the endogenous NIS gene. The NIS protein was also significantly higher and concentrated in the cell membrane compared to the cytoplasm.

Functional NIS activities following $^{131}$I uptake in MDA-hNIS cells when analyzed, showed a remarkable increase in uptake, reaching a maximum within 15 min, followed by a decline in 1 h. After 1 h of addition of $^{131}$I, the uptake level was maintained at 25% of the peak activity. These results showed that NIS overexpression in the MDA-hNIS cells increased the uptake of radioiodide compared to the control cells with low NIS expression and thus validates the functional NIS expression in ER-negative cell lines. Finally, the exposure of MDA-hNIS cells to $^{131}$I resulted in a time-dependent reduction in colony formation by 58% at 2 h and 64% at 6 h, compared with the survival of the control cells (MDA) which indicated that NIS overexpression enhanced the sensitivity to ER-negative breast cancer cells.

The NIS gene is well-known for its advantage as a reporter gene in the early diagnosis of many carcinomas. In a previous study (39), $^{131}$I SPECT revealed a clear image of recombinant baculovirus-infected tumors in vivo, and uptake of $^{131}$I in tumors was quantified which suggests that the NIS gene would be a promising tool for non-invasive monitoring of vector-mediated gene expression in vivo. Many studies have demonstrated a beneficial response to NIS-based radioiodide therapy in various tumors using tissue-specific promoters, including various cancer markers such as prostate-specific antigen (40), carcinoembryonic antigen (41) and calcitonin (42). However, some specific promoters exhibit lower activity levels than those of non-specific promoters, such as the CMV promoter. We found that following the use of lentivirus-mediated hNIS gene expression in an ER-negative cell line (MDA-hNIS), the iodine uptake assay demonstrated robust and functional NIS activity mediated by the CMV promoter. Moreover, the increased uptake of radioiodide resulted in a marked reduction in the survival rate of ER-negative breast cancer cells.

In conclusion, the present study is a novel method of upregulating the NIS gene expression in ER-negative breast cancer cells using a mammalian lentiviral vector, in order to increase the uptake of radioiodide and to reduce the survival rate of breast tumor cells in ER-negative breast cancer. The potential advantage of radiation inducible genetic constructs has been demonstrated in the so called ‘genetic radiotherapy’ strategy. The use of radioisotopes that accumulate in tumors offers an advantage for selective induction of exogenous genes. Our research suggests the development of a genetic radiation therapy by boosting NIS expression in ER-negative breast cancer tissues to increase the uptake of radioiodide and increase the susceptibility to radiation therapy for the treatment of breast cancer. This strategy may also prevent metastasis at an early stage in ER-negative breast cancer patients. The clinical applications of hNIS gene transfer is most promising to facilitate radioiodine ablation of locally invasive cancer cells that cannot be completely resected surgically. However, to fulfill this goal many issues need to be resolved, such as selective cytotoxicity in breast cancer cells by careful design and performing in vivo assays in experimental animal models.

Acknowledgements

The authors thank their colleagues who helped with the outcome data collection. This study was supported by Specialized Scientific Research Fund for the Young Teachers Program of the Sun Yat-Sen University (09ykpy45), Guangdong Natural Science Foundation (S201101000791) and Guangdong Medical Research Foundation (A20101026). We are grateful to 91SCI Company for language editing assistance.

References


